Financing Pharmaceutical Innovation: How Much Should Poor Countries Contribute?
We use a public economics framework to consider how pharmaceuticals should be priced when at least some of the R&D incentive comes from sales revenues. We employ familiar techniques of public finance to relax some of the restrictions implied in the standard use of Ramsey pricing. In the more general model, poor countries should not necessarily cover even their own marginal costs, and the pricing structure is not related to that which would be chosen by a monopolist in a simple way. We use this framework to examine on-going debates regarding the international patent system as embodied in the WTO’s TRIPS agreement.
When requesting a correction, please mention this item's handle: RePEc:cgd:wpaper:28. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (David Roodman)The email address of this maintainer does not seem to be valid anymore. Please ask David Roodman to update the entry or send us the correct email address
If references are entirely missing, you can add them using this form.